| __timestamp | Amneal Pharmaceuticals, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 3852327 |
| Thursday, January 1, 2015 | 109679000 | 839656 |
| Friday, January 1, 2016 | 118757000 | 4478145 |
| Sunday, January 1, 2017 | 109046000 | 16432324 |
| Monday, January 1, 2018 | 230435000 | 11890871 |
| Tuesday, January 1, 2019 | 289598000 | 34110000 |
| Wednesday, January 1, 2020 | 326727000 | 35781000 |
| Friday, January 1, 2021 | 365504000 | 40896000 |
| Saturday, January 1, 2022 | 399700000 | 52200000 |
| Sunday, January 1, 2023 | 429675000 | 59836000 |
Data in motion
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Amneal Pharmaceuticals, Inc. and Merus N.V., from 2014 to 2023.
Amneal Pharmaceuticals has seen a significant rise in SG&A expenses, growing by approximately 408% over the decade, peaking at $429 million in 2023. This increase reflects their aggressive expansion and market penetration strategies. In contrast, Merus N.V. has maintained a more conservative growth trajectory, with SG&A expenses increasing by around 1,454% to $60 million in the same period.
This stark contrast highlights differing strategic approaches: Amneal's focus on scaling operations versus Merus's emphasis on sustainable growth. Understanding these trends provides valuable insights into the financial health and strategic priorities of these companies.
Breaking Down SG&A Expenses: Novartis AG vs Merus N.V.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs Merus N.V.
Amneal Pharmaceuticals, Inc. or Rhythm Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Perrigo Company plc
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Merus N.V.